Growth Metrics

Novavax (NVAX) Gross Profit (2021 - 2025)

Novavax (NVAX) has 10 years of Gross Profit data on record, last reported at $125.0 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 142.12% year-over-year to $125.0 million; the TTM value through Dec 2025 reached $986.2 million, up 105.71%, while the annual FY2025 figure was $1.1 billion, 119.1% up from the prior year.
  • Gross Profit reached $125.0 million in Q4 2025 per NVAX's latest filing, up from $48.9 million in the prior quarter.
  • Across five years, Gross Profit topped out at $688.8 million in Q1 2022 and bottomed at -$85.2 million in Q2 2022.
  • Average Gross Profit over 5 years is $216.6 million, with a median of $167.7 million recorded in 2022.
  • Peak YoY movement for Gross Profit: tumbled 128.57% in 2022, then surged 1783.45% in 2025.
  • A 5-year view of Gross Profit shows it stood at $222.2 million in 2021, then fell by 20.96% to $175.6 million in 2022, then decreased by 22.36% to $136.4 million in 2023, then tumbled by 62.13% to $51.6 million in 2024, then surged by 142.12% to $125.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $125.0 million in Q4 2025, $48.9 million in Q3 2025, and $159.7 million in Q2 2025.